Telomerase Reverse Transcriptase Locus Polymorphisms and Cancer Risk: A Field Synopsis and Meta-Analysis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several recent studies have provided evidence that polymorphisms in the telomerase reverse transcriptase (TERT) gene sequence are associated with cancer development, but a comprehensive synopsis is not available. We conducted a systematic review and meta-analysis of the available molecular epidemiology data regarding the association between TERT locus polymorphisms and predisposition to cancer. METHODS: A systematic review of the English literature was conducted by searching PubMed, Embase, Cancerlit, Google Scholar, and ISI Web of Knowledge databases for studies on associations between TERT locus polymorphisms and cancer risk. Random-effects meta-analysis was performed to pool per-allele odds ratios for TERT locus polymorphisms and risk of cancer, and between-study heterogeneity and potential bias sources (eg, publication and chasing bias) were assessed. Because the TERT locus includes the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is in linkage disequilibrium with TERT, CLPTM1L polymorphisms were also analyzed. Cumulative evidence for polymorphisms with statistically significant associations was graded as "strong," "moderate," and "weak" according to the Venice criteria. The joint population attributable risk was calculated for polymorphisms with strong evidence of association. RESULTS: Eighty-five studies enrolling 490 901 subjects and reporting on 494 allelic contrasts were retrieved. Data were available on 67 TERT locus polymorphisms and 24 tumor types, for a total of 221 unique combinations of polymorphisms and cancer types. Upon meta-analysis, a statistically significant association with the risk of any cancer type was found for 22 polymorphisms. Strong, moderate, and weak cumulative evidence for association with at least one tumor type was demonstrated for 11, 9, and 14 polymorphisms, respectively. For lung cancer, which was the most studied tumor type, the estimated joint population attributable risk for three polymorphisms (TERT rs2736100, intergenic rs4635969, and CLPTM1L rs402710) was 41%. Strong evidence for lack of association was identified for five polymorphisms in three tumor types. CONCLUSIONS: To our knowledge, this is the largest collection of data for associations between TERT locus polymorphisms and cancer risk. Our findings support the hypothesis that genetic variability in this genomic region can modulate cancer susceptibility in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease
Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A., et al. (2008) · Nature · doi:10.1038/nature06846 · Cited by 1,523
Amos, C. I., Wu, X., Broderick, P., Gorlov, I. P., Gu, J., Eisen, T., Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J., et al. (2008) · Nature Genetics · doi:10.1038/ng.109 · Cited by 1,310
An exploratory test for an excess of significant findings
Ioannidis, J. P., & Trikalinos, T. A. (2007) · Clinical Trials · doi:10.1177/1740774507079441 · Cited by 751
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728 · cited 1×
“In light of the already abundant evidence linking telomerase activity to the development of many tumor types, many researchers are devising a variety of methods to target telomerase as a novel therapeutic approach potentially useful in a range of cancers (7,8); moreover, other investigators are testing the hypothesis…”
BackgroundTruong, T., Hung, R. J., Amos, C. I., Wu, X., Bickeböller, H., Rosenberger, A., Sauter, W., Illig, T., Wichmann, H.-E., Risch, A., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq178 · Cited by 194
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia
Calado, R. T., Regal, J. A., Hills, M., Yewdell, W. T., Dalmazzo, L. F., Zago, M. A., Lansdorp, P. M., Hogge, D., Chanock, S. J., Estey, E. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807057106 · Cited by 184
Bladder cancer SNP panel predicts susceptibility and survival
Andrew, A. S., Gui, J., Sanderson, A. C., Mason, R. A., Morlock, E. V., Schned, A. R., Kelsey, K. T., Marsit, C. J., Moore, J. H., & Karagas, M. R. (2009) · Human Genetics · doi:10.1007/s00439-009-0645-6 · Cited by 98
Cited by
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,220
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 624
Study, A. C., Bojesen, S. E., Study, A. O. C., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), (GENICA), G. E. I. A. B. C., (SWE-BRCA), S. B. C. S., The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), (EMBRACE), E. S. O. B. &. B. M. C., (GEMO), G. M. O. C. R. I. B. M. C., Pooley, K. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2566 · Cited by 528
Self-citationSideri, S., Papageorgiou, S. N., & Eliades, T. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.01.003 · Cited by 388
Biological invasions: a field synopsis, systematic review, and database of the literature
Lowry, E., Rollinson, E. J., Laybourn, A. J., Scott, T. E., Aiello‐Lammens, M. E., Gray, S. M., Mickley, J., & Gurevitch, J. (2013) · Ecology and Evolution · doi:10.1002/ece3.431 · Cited by 332
“Mocellin et al. 2012.”
Metadata
- Authors
- Mocellin, S., Verdi, D., Pooley, K. A., Landi, M. T., Egan, K. M., Baird, D. M., Prescott, J., De Vivo, I., & Nitti, D.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06-06
- Volume
- 104
- Issue
- 11
- Pages
- 840-854
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2117901243
- Cited by
- 129
- References
- 8
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telomerase Reverse Transcriptase Locus Polymorphisms and Cancer Risk: A Field Synopsis and Meta-Analysis. https://app.cochat.ai/papers/10.1093/jnci/djs222
- The paper
- Mocellin, S., Verdi, D., Pooley, K. A., Landi, M. T., Egan, K. M., Baird, D. M., Prescott, J., De Vivo, I., & Nitti, D. (2012). Telomerase Reverse Transcriptase Locus Polymorphisms and Cancer Risk: A Field Synopsis and Meta-Analysis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djs222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.